1.0 2009-07-21 20:27:35 UTC 2026-05-14 16:47:55 UTC T3D2881 Tranylcypromine SmallMolecule Tranylcypromine is an exogenous organic compound with the formula C9H11N and an average molecular weight of 133.19 g/mol. It exists as a solid at room temperature. Tranylcypromine belongs to the amines, a subclass of organonitrogen compounds within the organic compounds. This compound is found in antidepressants, as well as in other smoking requisites and pipe accessories within household cleaning and consumer products. The recorded route of exposure is oral. Tranylcypromine irreversibly inhibits monoamine oxidase (MAO), specifically targeting amine oxidase [flavin-containing] A (MAOA) and amine oxidase [flavin-containing] B (MAOB). Other protein targets include the D(2) dopamine receptor (DRD2) and the 5-hydroxytryptamine receptor 2A (HTR2A). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Because depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. Consequently, tranylcypromine is effective in the treatment of major depression, atypical depression, and dysthymic disorder. Additionally, it is useful in the treatment of phobic and panic disorders. Drug Synthetic Toxin Organic Compound Amine Drug Anti-Anxiety Agent Antidepressant Metabolite Monoamine Oxidase Inhibitor Synthetic Compound Antidepressive Agent Human Neurotoxin Jatrosom Parnate Tranilcipromina Transamine Tranylcypromin Tranylcyprominum C9H11N 133.1903 133.089149357 (1R)-2-phenylcyclopropan-1-amine tranylcypromine sulfate 155-09-9 N[C@@H]1CC1C1=CC=CC=C1 InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8?,9-/m1/s1 AELCINSCMGFISI-YGPZHTELSA-N Organic compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines Benzene and substituted derivatives Hydrocarbon derivatives Monoalkylamines Organopnictogen compounds Aralkylamine Aromatic homomonocyclic compound Benzenoid Hydrocarbon derivative Monocyclic benzene moiety Organopnictogen compound Primary aliphatic amine Primary amine Aromatic homomonocyclic compounds Detected and Not Quantified Exogenous Cytoplasm Extracellular Membrane Tranylcypromine Amine Oxidase Norepinephrine Antidepressant Action Pathway SMP0126672 Safinamide Action Pathway SMP0126696 Tranylcypromine Amine Oxidase Serotonin Antidepressant Action Pathway SMP0126744 Tranylcypromine Drug Metabolism SMP0130703 Tranylcypromine Drug Metabolism Action Pathway SMP0143195 Solid White powder. melting_point 79-80°C at 1.50E+00 mm Hg solubility 4.86E+004 mg/L logp 1.58 logp 1.50 ALOGPS logs -1.95 ALOGPS solubility 1.49e+00 g/l ALOGPS logp 1.34 ChemAxon pka_strongest_basic 9.62 ChemAxon iupac (1R)-2-phenylcyclopropan-1-amine ChemAxon average_mass 133.1903 ChemAxon mono_mass 133.089149357 ChemAxon smiles N[C@@H]1CC1C1=CC=CC=C1 ChemAxon formula C9H11N ChemAxon inchi InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8?,9-/m1/s1 ChemAxon inchikey AELCINSCMGFISI-YGPZHTELSA-N ChemAxon polar_surface_area 26.02 ChemAxon refractivity 41.7 ChemAxon polarizability 15.33 ChemAxon rotatable_bond_count 1 ChemAxon acceptor_count 1 ChemAxon donor_count 1 ChemAxon physiological_charge 1 ChemAxon formal_charge 0 ChemAxon Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this. Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS. Hepatic. Half Life: 1.5-3.2 hours in patients with normal renal and hepatic function No indication of carcinogenicity to humans (not listed by IARC). Primarily indicated for the treatment of clinical depression. It is generally used to remedy various types of mood and anxiety disorders, typically after a last resort only after conventional antidepressants have been tried without success. It also has some off-label uses, such as in the treatment of post-traumatic stress disorder (PTSD). [Wikipedia] #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f3bd3e1b2c8> In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma. Treatment should normally consist of general supportive measures, close observation of vital signs and steps to counteract specific symptoms as they occur, since MAO inhibition may persist. External cooling is recommended if hyperpyrexia occurs. Barbiturates have been reported to help relieve myoclonic reactions, but frequency of administration should be controlled carefully because Tranylcypromine may prolong barbiturate activity. When hypotension requires treatment, the standard measures for managing circulatory shock should be initiated. If pressor agents are used, the rate of infusion should be regulated by careful observation of the patient because an exaggerated pressor response sometimes occurs in the presence of MAO inhibition. (L1712) DB00752 HMDB14890 441233 CHEMBL1179 390008 C07155 Tranylcypromine GJZ Tranylcypromine 16927039 14574774 Drugs.com: http://www.drugs.com/cons/Tranylcypromine.html RxList: The Internet Drug Index (2009).: http://www.rxlist.com/ BE0000451 Tranylcypromine irreversibly inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. BE0002198 Tranylcypromine irreversibly inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. BE0002196 Tranylcypromine irreversibly inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. BE0000756 Tranylcypromine irreversibly inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms.